ALT001 safety study for cerebellar multiple system atrophy
Treatments studied
Part of Brain & nervous system clinical trials.
This early-stage trial tests a new biologic treatment called ALT001 in people with multiple system atrophy-cerebellar type (MSA-C), a rare neurological condition affecting balance and coordination. The study focuses on whether ALT001 is safe and whether it shows early signs of helping slow disease progression.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 30–75 years old
- Confirmed or probable MSA-C diagnosis (a brain disorder affecting balance) with symptoms for no more than 5 years
- Relatively mild motor symptoms on the standard MSA rating scale
- Expected to live at least 1 more year
- No other brain conditions or cancers that could cause similar symptoms
- Able to have an MRI scan and lumbar puncture (spinal tap) safely
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a gentle electrical current applied to the scalp can help people with a specific type of multiple system atrophy (the cerebellar variant) improve walking and other symptoms. The goal is to see if this non-invasive treatment is safe and effective.
This early-phase trial tests a new drug called ALT001 for people with multiple system atrophy (MSA). It aims to see if the drug is safe and may help slow the disease.
This trial tests a new treatment called Aleeto for people with a specific type of multiple system atrophy (MSA-P) who haven't responded well to standard Parkinson's medications. The goal is to see if Aleeto is safe and might help improve symptoms.
This study tests a new injection called NouvNeu001 for people with Multiple System Atrophy (MSA). The goal is to see if it can help control symptoms that standard treatments aren't managing well.
This study is collecting information from patients with multiple system atrophy (a rare neurological condition affecting movement and body functions), Parkinson disease, and healthy volunteers to better understand these conditions. By participating, you help doctors learn more about how these diseases develop and progress.
This phase 3 trial tests a new oral drug (MSA-01) for people with multiple system atrophy. It aims to see if the drug can slow disease progression and improve daily function.
Hear when a new Multiple System Atrophy - Cerebellar Subtype (MSA-C) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.